Skip to main content
SpringerLink
Log in

Thrombolytics

Drug Interactions of Clinical Significance

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Thrombolytic agents activate plasminogen and induce a systemic fibrinolytic and anticoagulant state. Interaction of fibrinolysis with coagulation and platelet aggregation might be important for synergistic interactions with other antiplatelet or anticoagulant drugs. Thrombolytic agents are most often used in patients with coexisting cardiovascular medication, including various antihypertensives, β-blocking agents, nitrates and aspirin (acetylsalicylic acid). In acute coronary syndromes, anticoagulants and antiplatelet compounds such as clopidogrel or glycoprotein IIb/IIIa receptor antagonists might be given.

Inducers or inhibitors of the cytochrome P450 system are not reported to affect the pharmacokinetics of any thrombolytic agent. Since the elimination of the recombinant plasminogen activators saruplase and alteplase is dependent on liver blood flow, drugs affecting hepatic blood flow could theoretically affect the hepatic clearance of these agents. In fact, a reduction in thrombolytic activity has only been demonstrated for alteplase with nitroglycerin (glyceryl trinitrate).

Pharmacodynamic interactions occur more often. The additive and beneficial effect of aspirin as concomitant therapy to thrombolysis has been demonstrated without excessive bleeding rates. No data are available on the interaction between ticlopidine or clopidogrel and thrombolytic agents in humans. Anticoagulation by heparin concomitantly with thrombolysis improves the patency rate of the occluded coronary vessel, but bleeding complications are seen more frequently. Although there has been no controlled study on the interaction between oral anticoagulants and thrombolytic agents, patients with myocardial infarction who were taking an oral anticoagulant before admission seem to be at higher risk for intracranial haemorrhage during thrombolytic therapy.

Currently, no recommendations can be given for possible dose adjustment of thrombolytic therapy in patients receiving antiplatelet comedication. For comedication with heparin, it has been advised to monitor activated partial thromboplastin time frequently and to avoid values >2.5-fold normal. Patients receiving thrombolytic treatment should be monitored frequently for bleeding and the physician should be aware of any comedication exerting antiplatelet (e.g. aspirin, clopidogrel and ticlopidine) or anticoagulant (e.g. warfarin) effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. Areport of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1996; 94: 2341–50

    Article  PubMed  CAS  Google Scholar 

  2. Gibson CM. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med 1999; 130: 841–7

    PubMed  CAS  Google Scholar 

  3. Gengo FM. The stroke pharmacopeia: promising experimental therapies. Pharmacotherapy 1998; 18 (3 Pt 2): S101–S107

    Google Scholar 

  4. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents-an overview. AnnHematol 1996; 73Suppl. 1: S9–S27

    CAS  Google Scholar 

  5. Lutomski DM, Bottorff M, Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet 1995; 28: 67–92

    Article  PubMed  CAS  Google Scholar 

  6. Iorio A, Agnelli G. Pharmacokinetic optimisation of the treatment of deep vein thrombosis. Clin Pharmacokinet 1997; 32: 145–72

    Article  PubMed  CAS  Google Scholar 

  7. De Boer A, Van Griensven J. Drug interactions with thrombolytic agents. Clin Pharmacokinet 1995; 28: 315–26

    Article  PubMed  Google Scholar 

  8. Pislaru S, Pislaru C, Szilard M, et al. In vivo effects of contrast media on coronary thrombolysis. J Am Coll Cardiol 1998; 32: 1102–8

    Article  PubMed  CAS  Google Scholar 

  9. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol 1991; 44: 1085–96

    Article  PubMed  CAS  Google Scholar 

  10. Mestre M, Uzan A, Sedivy P, et al. Enoxaparin (Clexane®, Lovenox®), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability. Thromb Res 1992; 66: 191–206

    Article  PubMed  CAS  Google Scholar 

  11. Becker RC, Caputo R, Ball S, et al. Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration. Am Heart J 1993; 126: 11–4

    Article  PubMed  CAS  Google Scholar 

  12. Herbert JM, Bernat A, Sainte-Marie M, et al. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993; 69: 268–71

    PubMed  CAS  Google Scholar 

  13. Bell Jr WR. Evaluation of thrombolytic agents. Drugs 1997; 54Suppl. 3: S11–S16

    Article  Google Scholar 

  14. Verstraete M, Fuster V. Thrombogenesis and antithrombotic therapy. In: Alexander WA, Schlant RC, Fuster V, editors. Hurst’s the heart, arteries and veins. t9th ed. New York (NY): McGraw-Hill, 1998: 1501–52

    Google Scholar 

  15. Alpert JS. Importance of the pharmacological profile of thrombolytic agents in clinical practice. Am J Cardiol 1991; 68 (16): E3–E7

    Article  Google Scholar 

  16. Hong SY, Yang DH, Kim PN. Urokinase concentration in the renal artery and vein. Nephron 1992; 61 (2): 176–80

    Article  PubMed  CAS  Google Scholar 

  17. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Google Scholar 

  18. Van Griensven JMT, Koster RW, Hopkins GR, et al. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. Thromb Haemost 1997; 78: 1015–20

    PubMed  Google Scholar 

  19. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984–94

    Article  PubMed  CAS  Google Scholar 

  20. Martin U, Kaufmann B, Neugebauer G. Current clinical use of reteplase for thrombolysis. Clin Pharmacokinet 1999; 36: 265–76

    Article  PubMed  Google Scholar 

  21. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–23

    Google Scholar 

  22. Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998; 79 (1): 134–9

    PubMed  CAS  Google Scholar 

  23. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581–7

    Google Scholar 

  24. Romeo F, Rosano GMC, Martuscelli E, et al. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J 1995; 130: 692–7

    Article  PubMed  CAS  Google Scholar 

  25. Nicolini FA, Ferrini D, Ottani F, et al. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis inpatients with acute myocardial infarction. Am J Cardiol 1994; 74: 662–6

    Article  PubMed  CAS  Google Scholar 

  26. De Boer A, Kluft C, Kasper FJ, et al. Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects. Br J Clin Pharmacol 1993; 36: 99–104

    Article  PubMed  Google Scholar 

  27. ISIS-3 (Third International Study of Infarct Survival)Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70

    Google Scholar 

  28. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1998; 31: 1466–73

    Article  PubMed  CAS  Google Scholar 

  29. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22: 381–9

    Article  PubMed  CAS  Google Scholar 

  30. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–35

    Article  PubMed  CAS  Google Scholar 

  31. Califf RM. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Am Heart J 1999; 138 (1 Pt 2): S12–S15

    Article  Google Scholar 

  32. Bednar MM, Quilley J, Russell SR, et al. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery 1996; 39: 352–9

    Article  PubMed  CAS  Google Scholar 

  33. Jones CR, Pasanisi F, Elliott HL, et al. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies. Br J Clin Pharmacol 1985; 20: 191–6

    Article  PubMed  CAS  Google Scholar 

  34. Verstraete M, Collen D. Pharmacology of thrombolytic drugs. J Am Coll Cardiol 1986; 8 (6 Suppl. B): B33–B40

    Article  Google Scholar 

  35. Bode C, Runge MS, Schonermark S, et al. Conjugation to antifibrin Fab’ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990; 81: 1974–80

    Article  PubMed  CAS  Google Scholar 

  36. Collen D, Stassen JM, Stump DC, et al. Synergism of thrombolytic agents in vivo. Circulation 1986; 74: 838–42

    Article  PubMed  CAS  Google Scholar 

  37. Tranchesi Jr B, Bellotti G, Chamone DF, et al. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction. Am J Cardiol 1989; 64: 229–32

    Article  PubMed  Google Scholar 

  38. Kirshenbaum JM, Bahr RD, Flaherty JT, et al. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group. Am J Cardiol 1991; 68 (17): 1564–9

    Article  PubMed  CAS  Google Scholar 

  39. Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarctio with alteplase. Am Coll Cardiol 1992; 20: 513–9

    Article  CAS  Google Scholar 

  40. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631–7

    Google Scholar 

  41. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction — a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627–33

    Article  PubMed  CAS  Google Scholar 

  42. Zahger D, Maaravi Y, Matzner Y, et al. Partial resistance to anticoagulation after streptokinase treatment for acute myocardial infarction. Am J Cardiol 1990; 66: 28–30

    Article  PubMed  CAS  Google Scholar 

  43. De Jaegere PP, Arnold AA, Balk AH, et al. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992; 19: 289–94

    Article  PubMed  Google Scholar 

  44. Jarvinen P, Aromaa U, Roiha M, et al. Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr 1978; 56: 801–4

    Article  PubMed  CAS  Google Scholar 

  45. Corot C, Chronos N, Sabattier V. In vitro comparison of the effects of contrast media on coagulation and platelet activation. Blood Coagul Fibrinolysis 1996; 7: 602–8

    Article  PubMed  CAS  Google Scholar 

  46. Grines CL, Schreiber TL, Savas V, et al. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 27: 1381–6

    Article  PubMed  CAS  Google Scholar 

  47. Melton LG, Dehmer GJ, Tate DA, et al. Variable influence of heparin and contrast agents on platelet function as assessed by the in vitro bleeding time. Thromb Res 1996; 83: 265–77

    Article  PubMed  CAS  Google Scholar 

  48. Dehmer GJ, Gresalfi N, Daly D, et al. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents. J Am Coll Cardiol 1995; 25: 1069–75

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology of the J.W. Goethe University, University Hospital, Theodor Stern Kai 7, D-60590, Frankfurt am Main, Germany

    Sebastian Harder & Ute Klinkhardt

Authors
  1. Sebastian Harder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ute Klinkhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian Harder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harder, S., Klinkhardt, U. Thrombolytics. Drug-Safety 23, 391–399 (2000). https://doi.org/10.2165/00002018-200023050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200023050-00004

Keywords

Search

Navigation